RxDoctor Payments Data

Kristina Christian, MD

Internal Medicine · Greenup, KYNPI 1194043364

Payments from drug & device makers

$1,827in general payments, 2019–2025

Across 122 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$278
  • Lilly USA, LLC$104
  • AstraZeneca$88
  • Pfizer$83
  • Abbott$52
  • plus $141 from 7 others

What the payments were for

  • Food & beverage$1,827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,827 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$65,921
Medicare patients
152
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin137$148,925
XifaxanRifaximin26$83,170
OzempicSemaglutide68$66,345
MounjaroTirzepatide57$59,773
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$56,976
RybelsusSemaglutide35$55,996
TrulicityDulaglutide24$24,446
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$16,827
Ondansetron Hcl40$13,947
JanuviaSitagliptin Phosphate18$13,440
Breo ElliptaFluticasone/Vilanterol24$13,319
XareltoRivaroxaban15$11,547
FarxigaDapagliflozin Propanediol11$10,528
LinzessLinaclotide13$10,476
VascepaIcosapent Ethyl21$8,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$17$148,925137 claims
Novo NordiskOzempic, Rybelsus$278$122,341103 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,081$87,121117 claims
Lilly USA, LLCMounjaro, Trulicity$104$84,22081 claims
AstraZenecaFarxiga$88$10,52811 claims
Kowa Pharmaceuticals America, Inc.Livalo$12$6,04115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Greenup

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →